Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2020-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single-arm, non-randomized feasibility and Phase I trial of 20(S) Camptothecin Propionate administered orally. CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohorts of 3+3 patients will be treated. CZ48 will be administered orally daily (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink up to one gallon of fluid daily if possible to flush the bladder to mitigate cystitis. Cystitis is an anticipated toxicity as CZ48 is a pro-drug of CPT (Camptothecin)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma

NCT00947739

Advanced Solid Tumors Lymphomas

COMPLETED PHASE1

A Study of CBP-1018 in Patients With Advanced Solid Tumors

NCT04928612

Solid Tumor

RECRUITING PHASE1

Subjects With Advanced or Metastatic Solid Tumor Malignancies

NCT05474859

Metastatic Solid Tumor Advanced Solid Tumor

NOT_YET_RECRUITING PHASE1

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

NCT01140607

Neoplasm Malignant

COMPLETED PHASE1

A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors

NCT01755390

Advanced Solid Tumor

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

• To describe the dose limiting toxicities and adverse event profile of Camptothecin-20-O-Propionate hydrate (CZ48) administered orally every day for 4 weeks (1 course).

SECONDARYOBJECTIVE

* To determine the Maximum Tolerated Dose (MTD) of Camptothecin-20-O-Propionate hydrate (CZ48).
* To determine the blood plasma levels (PK study) of orally administered CZ48.
* To assess responses by Response Evaluation Criteria in Solid Tumors (RECIST) criteria when applicable.
* To follow patients for survival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Lymphoma of Extranodal and/or Solid Organ Site Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment population

The study drug, CZ48, is administered orally in capsule form t.i.d. Capsules in 30mg and 50mg of drug are available for dosing. This is a dose escalation study so dosage has not yet been determined. Study drug is take on day 1 - 5 and then no drug on day 6 and 7. This is repeated for 4 weeks, or one course.

Group Type EXPERIMENTAL

CZ48

Intervention Type DRUG

CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CZ48

CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Camptothecin-20-O-Propionate hydrate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have a Performance Status (Zubrod) performance status of 0-1
* Patients must sign an informed consent document
* Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of \> 1,500 /mm3 and platelet count \>100,000/mm3 along with an absence of a red blood cell transfusion in the two weeks prior to their participation in the trial
* Patients should have adequate hepatic function with a total bilirubin within normal range and serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) \< two times the upper limit of normal (ULN) for patients without liver metastasis and SGOT or SGPT \< five times ULN for those with liver metastasis, and adequate renal function as defined by a serum creatinine within 1.5 times the upper limit of normal.
* Patients may receive no other concurrent anticancer treatments such as chemotherapy, hormone therapy (except for prostate cancer patients on luteinizing hormone-releasing hormone ((LHRH)) agonists), immunotherapy, biological agents, investigational agents, or radiation therapy during this trial, and should be off these treatments for at least 2 weeks, or until they have completely recovered from the side effects of these treatments, whichever is longest, except for persistent grade 1 neuropathy in patients who received prior platinum or taxanes.

Exclusion Criteria

* Patients with symptomatic brain metastases are excluded from this study.
* Patients with brain metastasis that have been treated, asymptomatic and off any steroid use are permitted for study
* Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception (contraceptive pill, or intrauterine device ((IUD)), or two mechanical barriers).
* Patients with severe uncontrolled medical problems are not eligible for this trial.
* Patients who have too much esterase as determined by a pre-screen dose, with a conversion rate yielding concentration of CPT \> 100 ng/ml in vitro.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No